The effect of phenobarbital on the transcriptional activity of liver

Cytochrome P450 expression and regulation in the brain

The regulation of brain cytochrome P450 enzymes (CYPs) is different compared with respective hepatic enzymes. This may result from anatomical bases and physiological functions of the two organs. The brain is composed of a variety of functional structures built of different interconnected cell types endowed with specific receptors that receive various neuronal signals from other brain regions. Those signals activate transcription factors or alter functioning of enzyme proteins. Moreover, the blood-brain barrier (BBB) does not allow free penetration of all substances from the periphery into the brain. Differences in neurotransmitter signaling, availability to endogenous and exogenous active substances, and levels of transcription factors between neuronal and hepatic cells lead to differentiated expression and susceptibility to the regulation of CYP genes in the brain and liver. Herein, we briefly describe the CYP enzymes of CYP1-3 families, their distribution in the brain, and discuss brain-specific regulation of CYP genes. In parallel, a comparison to liver CYP regulation is presented. CYP enzymes play an essential role in maintaining the levels of bioactive molecules within normal ranges. These enzymes modulate the metabolism of endogenous neurochemicals, such as neurosteroids, dopamine, serotonin, melatonin, anandamide, and exogenous substances, including psychotropics, drugs of abuse, neurotoxins, and carcinogens. The role of these enzymes is not restricted to xenobiotic-induced neurotoxicity, but they are also involved in brain physiology. Therefore, it is crucial to recognize the function and regulation of CYP enzymes in the brain to build a foundation for future medicine and neuroprotection and for personalized treatment of brain diseases.

The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors

Numerous chemicals increase the metabolic capability of organisms by their ability to activate genes encoding various xenochemical-metabolizing enzymes, such as cytochromes P450 (CYPs), transferases and transporters. For example, natural and synthetic glucocorticoids (agonists and antagonists) as well as other clinically important drugs induce the hepatic CYP2B, CYP2C and CYP3A subfamilies in man, and these inductions might lead to clinically important drug-drug interactions. Only recently, the key cellular receptors that mediate such inductions have been identified. They include nuclear receptors, such as the constitutive androstane receptor (CAR, NR1I3), the retinoid X receptor (RXR, NR2B1), the pregnane X receptor (PXR, NR1I2), and the vitamin D receptor (VDR, NR1I1) and steroid receptors such as the glucocorticoid receptor (GR, NR3C1). There is a wide promiscuity of these receptors in the induction of CYPs in response to xenobiotics. Indeed, this adaptive system appears now as a tangle of networks, where receptors share partners, ligands, DNA response elements and target genes. Moreover, they influence mutually their relative expression. This review is focused on these different pathways controlling human CYP2B6, CYP2C9 and CYP3A4 gene expression, and the cross-talk between these pathways.

Prenatal and neonatal pharmacologic stress on early behavior and sexual maturation in the hamster

Exposure to phenobarbital in utero results in sex-dependent altered neonatal behavior and reproductive maturation in hamsters. Prenatal phenobarbital-exposed (40 mg/kg subcutaneous to pregnant dams) male pups have at least 30% less pivoting activity and ultrasonic calling (high-frequency sounds produced by pups when separated from the nest) when compared with control pups born to saline-injected dams. As prenatal phenobarbital-treated male and female hamsters mature, there is a dose-dependent (20, 40, and 60 mg/kg) 2- to 5-day delay, respectively, according to sex, in puberty onset. Both sexes exhibited 30% lighter than control's adrenal weights associated with prenatal phenobarbital exposure. Although gonadal weights for males exposed to phenobarbital in utero were not affected, females had up to 33% lighter ovarian weights when compared with controls. Females exposed to phenobarbital in utero also had approximately 40% more irregular estrous cycles. Gonadal hormones act by means of Central Releasing Factor on pituitary ACTH secretion. Additional treatment during the neonatal period with 10 IU ACTH decreased the percentage of irregular estrous cycles and shortened the delay in puberty onset to near-control values in prenatally phenobarbital-treated females.

Induction of UDP-glucuronyl transferase mRNA in embryonic chick livers by phenobarbital

Administration of phenobarbital to chick embryos increased hepatic microsomal UDP-glucuroyltransferase activity some 25-fold. The large phenobarbital-induced increase of UDP-glucuronyltransferase activity was correlated to an equivalent increase of immunochemically measurable UDP-glucuronyltransferase protein. Poly(A+) RNA isolated from the livers of chick embryos treated with either phenobarbital or saline was translated in vitro. Immunochemical analysis of the translation products indicated that phenobarbital induced a 30-fold increase in UDP-GT mRNA. Fractionation of hepatic poly(A+) RNA from phenobarbital-treated chick embryos by sucrose density gradient centrifugation indicated that the size of the UDP-GT mRNA was 21S. These data show that phenobarbital induction of chick embryo liver UDP-glucuronyltransferase activity correlates with a similar large increase in the level of translatable mRNA for this enzyme.

The effect of phenobarbital on protein metabolism of liver. Results with isolated hepatocytes

A technique has been devised which makes use of an amino acid alternatively labeled with either [14C] or [3H], and permits the simultaneous evaluation of synthesis, catabolism and secretion by the same sample of isolated rat liver cells during the same time-period of incubation. This technique has been used to study protein metabolism of liver cells isolated from rats treated with 4 doses of phenobarbital (8 mg/100 g body weight) given in the 4 days before killing the animals. Total protein synthesis and secretion do not change in phenobarbital-treated rats; albumin represents 40% of secreted protein in both normal and treated rats. On the contrary, the parameters which indicate protein degradation are lower in phenobarbital-treated than in normal rats, showing that protein catabolism is appreciably reduced in the liver cells obtained from rats treated with phenobarbital.